Westwood Holdings Group Inc. decreased its stake in Becton Dickinson (NYSE:BDX) by 26.7% in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 757,899 shares of the medical instruments supplier’s stock after selling 275,585 shares during the quarter. Becton Dickinson makes up about 1.3% of Westwood Holdings Group Inc.’s holdings, making the stock its 14th biggest position. Westwood Holdings Group Inc. owned approximately 0.28% of Becton Dickinson worth $164,237,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other hedge funds also recently added to or reduced their stakes in BDX. Amica Retiree Medical Trust lifted its position in Becton Dickinson by 325.0% in the 4th quarter. Amica Retiree Medical Trust now owns 510 shares of the medical instruments supplier’s stock worth $109,000 after buying an additional 390 shares in the last quarter. Almanack Investment Partners LLC. purchased a new stake in Becton Dickinson in the 4th quarter worth approximately $109,000. Advisors Preferred LLC purchased a new stake in Becton Dickinson in the 4th quarter worth approximately $126,000. Truewealth LLC purchased a new stake in Becton Dickinson in the 4th quarter worth approximately $133,000. Finally, Penserra Capital Management LLC purchased a new stake in Becton Dickinson in the 4th quarter worth approximately $136,000. Institutional investors own 84.26% of the company’s stock.
In related news, Director David F. Melcher bought 500 shares of the company’s stock in a transaction on Monday, May 7th. The stock was bought at an average cost of $225.07 per share, with a total value of $112,535.00. Following the completion of the purchase, the director now owns 2,728 shares in the company, valued at approximately $613,990.96. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Alexandre Conroy sold 20,128 shares of the business’s stock in a transaction dated Monday, May 21st. The stock was sold at an average price of $228.74, for a total transaction of $4,604,078.72. Following the completion of the transaction, the insider now directly owns 35,583 shares of the company’s stock, valued at $8,139,255.42. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 32,214 shares of company stock valued at $7,338,413. Insiders own 1.00% of the company’s stock.
BDX has been the subject of a number of research analyst reports. ValuEngine upgraded shares of Becton Dickinson from a “hold” rating to a “buy” rating in a research report on Wednesday, April 18th. Zacks Investment Research downgraded shares of Becton Dickinson from a “buy” rating to a “hold” rating in a research report on Tuesday, March 6th. Morgan Stanley raised their price target on shares of Becton Dickinson from $245.00 to $250.00 and gave the company an “equal weight” rating in a report on Wednesday, February 7th. Citigroup upgraded shares of Becton Dickinson from a “neutral” rating to a “buy” rating and raised their price target for the company from $237.00 to $251.00 in a report on Tuesday, April 10th. Finally, BMO Capital Markets assumed coverage on shares of Becton Dickinson in a report on Monday, March 5th. They set a “market perform” rating and a $249.00 price target on the stock. Six investment analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $241.19.
Becton Dickinson opened at $231.61 on Thursday, Marketbeat Ratings reports. Becton Dickinson has a 1 year low of $187.27 and a 1 year high of $248.39. The company has a current ratio of 1.70, a quick ratio of 1.12 and a debt-to-equity ratio of 1.07. The firm has a market capitalization of $60.85 billion, a P/E ratio of 24.43, a PEG ratio of 1.58 and a beta of 1.12.
Becton Dickinson (NYSE:BDX) last issued its earnings results on Thursday, May 3rd. The medical instruments supplier reported $2.65 earnings per share for the quarter, beating the consensus estimate of $2.63 by $0.02. Becton Dickinson had a negative net margin of 0.46% and a positive return on equity of 14.27%. The business had revenue of $4.22 billion for the quarter, compared to analyst estimates of $4.12 billion. During the same period in the previous year, the business earned $2.30 EPS. The firm’s revenue was up 42.2% on a year-over-year basis. research analysts forecast that Becton Dickinson will post 10.99 EPS for the current year.
The business also recently announced a quarterly dividend, which will be paid on Friday, June 29th. Shareholders of record on Friday, June 8th will be paid a $0.75 dividend. This represents a $3.00 dividend on an annualized basis and a dividend yield of 1.30%. The ex-dividend date is Thursday, June 7th. Becton Dickinson’s dividend payout ratio is presently 31.65%.
Becton Dickinson Company Profile
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. It operates in two segments, BD Medical and BD Life Sciences. The BD Medical segment offers syringes, pen needles, and other products for diabetes; needles, syringes, and intravenous catheters for medication delivery; prefilled IV flush syringes; regional anesthesia needles and trays; sharps disposal containers; closed-system transfer devices; skin antiseptic products; surgical and laparoscopic instrumentations; intravenous medication safety and infusion therapy delivery, and automated medication dispensing and supply management systems; medication inventory optimization and tracking systems; and prefillable drug delivery systems.
Receive News & Ratings for Becton Dickinson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and related companies with MarketBeat.com's FREE daily email newsletter.